CAY10566

CAY10566 is a potent, selective, and orally bioavailable small molecule inhibitor of stearoyl-CoA desaturase 1 (SCD1). It exhibits IC50 values of 4.5 nM and 26 nM for mouse and human SCD1, respectively. Developed primarily as a research tool by Cayman Chemical, CAY10566 blocks the conversion of saturated long-chain fatty acid-CoAs to monounsaturated fatty acids. In preclinical studies, it has demonstrated tumor growth inhibition, particularly in Akt-driven models, and has been used to investigate the role of lipid metabolic reprogramming in hepatocellular carcinoma metastasis and invasion. It is currently used for research purposes and is not approved for clinical use in humans.

Other names

3-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)pyridazine